Cascala Health, a Boston, MA-based healthcare technology company, raised $8.6M in seed financing.

The round was co‑led by Flare Capital Partners and Eniac Ventures, with participation from Omega Healthcare Investors, Ziegler Link-age Fund, Tau Ventures, and Digital Health Venture Partners, bringing Cascala’s total funding to $11.23M since its launch in mid-2024.

The company intends to use the funds to accelerate product development, expand its clinical intelligence capabilities, and support the growth of its customer implementation team.

Led by Matt A. Murphy, CEO and Co-Founder, Cascala Health delivers a clinically responsible AI intelligence layer for care teams and post-acute care operators. It combines AI-powered insights, real-time communication tools, and clinical reasoning to guide care teams through each moment in the patient journey. Its AI‑enabled clinical intelligence platform integrates with any web‑based EMR or population health platform to streamline workflows, surface personalized interventions, and support risk‑bearing organizations in delivering better care transitions and ongoing disease management.

In active deployments with early customers, Cascala’s care transitions platform already orchestrates care for more than 300,000 patients across thousands of post-acute transitions. It also extends into the larger patient care team, empowering more than 3,000 primary-care clinicians to actively engage in their patients’ post-acute journey.

Originally announced August 20th, 2025